Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Legend Biotech Corp ADR (NASDAQ: LEGN) was $35.08 for the day, up 1.39% from the previous closing price of $34.6. In other words, the price has increased by $1.39 from its previous closing price. On the day, 1.66 million shares were traded. LEGN stock price reached its highest trading level at $35.3 during the session, while it also had its lowest trading level at $34.61.
Ratios:
Our analysis of LEGN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.57 and its Current Ratio is at 4.71. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Redburn Atlantic on October 08, 2024, initiated with a Buy rating and assigned the stock a target price of $86.
On June 17, 2024, Truist started tracking the stock assigning a Buy rating and target price of $88.
H.C. Wainwright reiterated its Buy rating for the stock on May 24, 2024, while the target price for the stock was revised from $86 to $73.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 23 ’25 when Huang Ying bought 15,291 shares for $45.04 per share.
Yeung Jessie bought 642 shares of LEGN for $28,890 on Jul 23 ’25. On Jun 26 ’25, another insider, Casey Patrick John, who serves as the Director of the company, bought 1,000 shares for $33.23 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 6474751488 and an Enterprise Value of 12369838080. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.11 while its Price-to-Book (P/B) ratio in mrq is 6.25. Its current Enterprise Value per Revenue stands at 15.524 whereas that against EBITDA is -59.182.
Stock Price History:
The Beta on a monthly basis for LEGN is 0.29, which has changed by -0.38086832 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, LEGN has reached a high of $59.62, while it has fallen to a 52-week low of $27.34. The 50-Day Moving Average of the stock is -7.19%, while the 200-Day Moving Average is calculated to be -2.00%.
Shares Statistics:
LEGN traded an average of 1.55M shares per day over the past three months and 1011730 shares per day over the past ten days. A total of 184.57M shares are outstanding, with a floating share count of 180.77M. Insiders hold about 2.06% of the company’s shares, while institutions hold 44.88% stake in the company. Shares short for LEGN as of 1753920000 were 7822995 with a Short Ratio of 5.05, compared to 1751241600 on 10443597. Therefore, it implies a Short% of Shares Outstanding of 7822995 and a Short% of Float of 8.1499994.
Earnings Estimates
The firm’s stock currently is rated by 5.0 analysts. The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.0 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.08 and -$1.46 for the fiscal current year, implying an average EPS of -$0.67. EPS for the following year is $0.41, with 5.0 analysts recommending between $0.55 and $0.29.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 11 analysts. It ranges from a high estimate of $314.19M to a low estimate of $260M. As of the current estimate, Legend Biotech Corp ADR’s year-ago sales were $160.21MFor the next quarter, 11 analysts are estimating revenue of $337.45M. There is a high estimate of $399.06M for the next quarter, whereas the lowest estimate is $280M.
A total of 17 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $1.14B, while the lowest revenue estimate was $990.11M, resulting in an average revenue estimate of $1.06B. In the same quarter a year ago, actual revenue was $627.24MBased on 17 analysts’ estimates, the company’s revenue will be $1.57B in the next fiscal year. The high estimate is $1.95B and the low estimate is $1.22B.
